CombiGene featured in a major article in Nature, one of the world’s leading scientific journals

The latest number of Nature (Vol. 564 Issue 7735, 13 December 2018) features CombiGene’s operations, and the possibilities of using gene therapy to treat epilepsy, in a major article. Both CombiGene’s scientific founder, Professor Merab Kokaia, and CEO Jan Nilsson, are quoted.

“CombiGene being featured in Nature like this makes me incredibly happy and proud. It is a clear sign that our research and development is beginning to attract international attention. With this fantastic conclusion to 2018, we will be going into 2019 even stronger and even more inspired,” says CombiGene CEO Jan Nilsson.

Read the entire article here:
https://www.nature.com/magazine-assets/d41586-018-07644-y/d41586-018-07644-y.pdf

CombiGene AB (publ)
Jan Nilsson, VD
Tel: +46 (0)704 66 31 63
jan.nilsson@combigene.com

About CombiGene AB
CombiGene’s business concept is to develop effective gene
therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen,

CombiGene has offices at Medicon Village in Lund, Sweden.
The company is public and listed on the Swedish marketplace Spotlight.